Reductive amination of the C-20 aldehyde group of tylosin and related macrolides yielded a large series of derivatives with potentially useful antibiotic properties. Evaluation of these new compounds was conducted on the basis of: 1) Broad antimicrobial spectrum in vitro, with particular emphasis on inhibition of Pasteurella multocida and Pasteurella haemolytica; 2) in vivo efficacy, especially when given orally, against P. multocida in experimental infections in chicks; and 3) bioavailability after oral administration to laboratory animals. The most useful activity was found within a series of derivatives produced by reductive amination of desmycosin with secondary amines.
Tylosin is an important and well-established antibiotic in veterinary medicineX); it is orally effective against infections in poultry and pigs due to Gram-positive bacteria and Mycoplasma gallisepticum as well as certain Gram-negative bacteria such as Fusobacterium necrophorum, a causative agent of liver abscesses in cattle2). A variety of chemical modifications of the C-20 aldehyde group in tylosin and related macrolide antibiotics have recently been reported, which improved efficacyagainst experimental infections and bioavailability in animals after oral administration3*. Fromour extensive evaluation of several series of macrolide derivatives, potentially useful activity was found in a compound obtained by reductive amination of desmycosin, which resulted in an expansion of the effective antimicrobial spectrum of tylosin to include both Pasteurella multocida and Pasteurella haemolyticaA). These Gram-negative bacteria are important pathogens responsible for respiratory illness and mortality in both cattle and pigs5)6). Since a macrolide antibiotic which could be administered both parenterally and orally for the treatment of infections caused by Pasteurella species wouldbe a useful contribution to veterinary medicine, an extensive exploration of the structure-activity relationships amongreductively aminated derivatives of macrolides was warranted. In this paper, we report the results of our studies on numeroussuch derivatives oftylosin-reiated macrolides.
Results and Discussion

Synthesis of Reductive Amination Derivatives
The effects of reductive amination of the aldehyde group in 16-membered macrolide antibiotics have antibiotic, but a dimeric derivative (20,20/-dideoxo-20,20 ' -iminoditylosin) had good antimicrobial activity8*. In a subsequent study, reductive amination of tylosin and desmycosin was performed with a variety of primary and secondary amines, yielding a series of secondary and tertiary amino derivatives; several of these compoundsdemonstrated good antimicrobial activity both in vitro and in vivo against Gram-positive bacteria9*.
During this period, a new series of derivatives of 5-Omycaminosyltylonolide (OMT)was reported, in which activity against Gram-negative bacteria was significantly increased when the C-23 substituent of OMT was converted into certain tertiary amino groups10*. Our reductive amination of desmycosin or lactenocin with hexamethyleneimine (one of the C-23 amino substituents which increased activity of OMT)10*yielded new macrolide derivatives which exhibited activity against P. multocida both in vitro and in vivoA\ This unexpected and novel result prompted our synthesis ofa large number ofreductively aminated derivatives in order to define the structure-activity relationships and to determine whether a suitable candidate for use in veterinary medicine could be identified.
Standard reductive amination procedures employing sodium cyanoborohydride proved very suitable for the synthesis of a wide variety of derivatives (Scheme I)11*. Selective modification of the aldehyde function was easily accomplished under these mild conditions, with no interference from side reactions such as reduction of the C-9 ketone. Derivatives were prepared from both primary and secondary amines, but the latter were emphasized because of the superior antimicrobial properties of the tertiary amino derivatives (see below). Also, as a result of our initial antimicrobial evaluation, we prepared a greater number of derivatives which possessed aliphatic 7V-alkyl groups in which the total number of carbon atoms of the amino substituents ranged from six to about fourteen. Reductive aminations were conducted using both acyclic and cyclic secondary amines and incorporated both unsaturation and hetero atom substitutions Scheme1. Reaction schemeand structures ofreductively aminated derivatives oftylosin-related macrolides. within the amino substituents. Approximately one hundred reductive amination derivatives oftylosin-related macrolides have been prepared and evaluated. Additional details of the synthesis and evaluation of one particular group of derivatives, prepared from desmycosin and cyclic secondary amines, have been recently reported12).
The new compoundswere isolated by standard extractive procedures and purified by precipitation from aqueousacidic solution upon addition of aqueoussodiumhydroxide; whennecessary, further purification was accomplished by chromatographic methods12). The new products were fully characterized by their XH NMR, IR, UV and MS (Tables 1 and 2 ).
Evaluation of Reductive Amination Derivatives of Desmycosin: In Vitro Activity All of the derivatives which were prepared by reductive amination of tylosin, desmycosin and related 1 6-membered macrolides exhibited some antimicrobial activity in vitro (Table 3) . Representative pathogens from both clinical and veterinary medicine were employed in the initial in vitro screening tests. Derivatives with a primary amino group at C-20 (compound 1) or possessing one or two methyl groups on the amino 12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54 group (compounds 2, ll, 45, 48, 52 and 55) were among the least active compounds tested. Activity was improved as the size of the 2O-7V-alkyl substituents increased beyond that of methyl, ethyl and small branched alkyl groups (such as found in compounds 3, 12, 14 and 18). An upper limit to the size of the 7V-alkyl substituents was not very well defined in terms of in vitro activity, whichwas only moderately reduced even with derivatives possessing such large C-20 substituents as (norbornyl)dodecylamino and (cyclooctyl)dodecylamino (compounds 25 and 26). The demycarosyl derivatives of tylosin and related macrolides are known to have improved activity in vitro against Gram-negative bacteria, including the important veterinary pathogens P. multocida and P. haemolytica4A3). A similar trend was observed with the reductively aminated derivatives; these C-20 amino derivatives of tylosin, macrocin and 3"'-O-demethylmacrocin (DOMM) had weak activity against Pasteurella species, whereas the analogous demycarosyl derivatives from desmycosin, lactenocin, 3"-0-demethyllactenocin (DOML) and OMTpossessed good in vitro activity against both Pasteurella species (Table 3) . Consequently, our principal effort was focused upon the demycarosyl derivatives as offering the best chance to significantly expand the useful antimicrobial spectrum of tylosin. The optimum in vitro activity was achieved in those derivatives of desmycosin which possessed C-20 aminoalkyl substituents having approximately six to fourteen carbon atoms. Within this range, the aminoalkyl group could either be cyclic or acyclic, saturated or unsaturated (with double bonds, triple bonds or aromatic rings) or contain additional heteroatoms such as nitrogen, oxygen, sulfur or halogen. However, it was not possible to distinguish much further among the members of this relatively large group on the basis of their in vitro activity. In Vivo Activity Because it was difficult to choose from the many membersof this series of derivatives on the basis of their in vitro activity, their in vivo activity became the critical parameter for selecting the potentially most useful antimicrobial compounds. In vivo activity was initially assessed in two different model experimental infections. Efficacy against a typically susceptible Gram-positive bacterium, Streptococcus pyogenes, was measured in a traditional mouseinfection model, whereas efficacy against P. multocida was determined in chicks, due to the greater reproducibility of our results in this experimental infection model4).
Compounds were generally tested by both the parenteral and oral routes, since antimicrobial efficacy by both routes of administration was being sought. As reported previously, the C-20 modified derivatives of desmycosin were generally efficacious against infections by Gram-positive bacteria in mice and, in particular, were more efficacious than tylosin or desmycosin whenadministered orally3). A substantial numberof the C-20 aminoalkyl derivatives of desmycosin followed this same pattern, exhibiting good efficacy when administered orally against the experimental infection by S. pyogenes (Table 4 ). The C-20 aminoalkyl derivatives possessing either small substituents (compounds 1, 2, ll, 45 and 48) or large substituents (compounds 10, 24, 25 and 26) were not orally active, which helped define the range of compounds with potentially useful oral efficacy. The C-20 aminoalkyl derivatives of OMT(compounds 52~56 and 64~69) were all inactive when given orally, in spite of their good in vitro activity and, in many cases, their good in vivo activity whengiven parenterally.
In vivo activity of the derivatives against Pasteurella was investigated in a chick infection model to further define the range of effective antibiotic compounds. In this preliminary in vivo screen, a dose of 30mg/kg was used subcutaneously while an oral dose of 0.53g/liter was administered in the drinking water of the chicks. All compounds with an MICvalue against Pasteurella of 6.25//g/ml or less, as well as some derivatives with higher MICvalues, were evaluated in vivo. Based upon results from the preliminary in vivo tests, dose titration studies were then performed to select the compoundswith the best in vivo activity. Although an inevitable amount of test-to-test variability was present, this experimental infection provided a suitable basis for selecting the most efficacious compounds. This chick Pasteurella test represented a relatively severe infection and consequently posed a serious challenge to the compoundsfor demonstrating in vivo activity. While a number of the reductive amination derivatives, when given subcutaneously, treated the Pasteurella infection quite well at 30 mg/kg or even at lower doses, very few compoundsclearly stood out as efficaciouswhenadministered orally in the drinking water of the chicks. Amongthe acyclic aminoalkyl compounds, the better candidates appeared to be those tertiary amino derivatives with alkyl groups of three to five carbon atoms in length, such as the di(n-propyl)amino, the di(sec-butyl)amino and the ethyl(2-methylbutyl)amino derivatives of desmycosin (compounds 13, 17 and 19). In contrast, many of the cyclic aminoalkyl derivatives, exemplified by the 3,5-dimethylpiperidinyl derivative (40), appeared to be somewhat more reproducibly efficacious in this model Pasteurella infection in chicks and have been reported separately12).
As previously reported for other aldehyde-modified derivatives of desmycosin3), the derivatives obtained by reductive amination of desmycosin gave higher blood levels than either desmycosin or tylosin in both rats and chicks after oral administration (Table 5) . Furthermore, higher concentrations were achieved more consistently in chicks than in rats. The combination of excellent efficacy in two distinctly different models of experimental infections, utilizing two different animal species and two different bacteria, along with results demonstrating good bioavailability after oral administration, indicated that a useful neworal antibiotic could be selected from this series of reductive amination derivatives of desmycosin. In order to better distinguish among the number of these derivatives which appeared to exhibit the desired characteristics, a smaller group was selected for further evaluation in the target animals, calves and pigs. Included from the present series as the best candidates were the di(«-propyl)amino derivative (compound 13) and the ethyl(2-methylbutyl)amino derivative (compound 19) of desmycosin, along with representatives of the cyclic aminoalkyl derivatives, as exemplified by the 3,5-dimethylpiperidinyl derivative Mean concentration (wg/ml) per sample period (compound 40) of desmycosin. From these more extensive investigations, the latter compound (40) was selected as the best candidate for further development. Nowgenerically known as tilmicosin (originally designated as EL-870), it is being investigated for the treatment of pneumonia in cattle and pigs6)14'15).
Experimental Materials and Methodŝ
NMRspectra were measured in CDC13solution on a Bruker WH-360or Jeol FX90Aspectrometer; chemical shifts are given in ppm down field from internal TMS.Field desorption mass spectra (FD-MS) were obtained on a Varian-MAT73 1 spectrometer with carbon dendrite emitters. UVspectra were measured in 95% ethanol solution on a Cary 219 spectrometer. TLC was performed using E. Merck plates of Silica gel 60 with a fluorescent indicator (F-254); visualization was effected by UVlight. Product purification was performed by chromatography on silica gel, using either flash chromatography16) (E. Merck grade 60 silica gel) or a Waters Model 500 Prep LC system.
In vivo evaluations against S. pyogenes infections in mice were conducted by treating infected animals 1 and 5 hours post-infection, either subcutaneously or by gavage, with 0.25 ml of a 10% aqueous ethanolic solution of the compoundover a range of concentrations; tartaric acid was added whenneeded to dissolve the compounds.In vivo evaluations against P. multocida were performed by treating infected 1-day-old chicks with the test compound, either subcutaneously at 1 and 4 hours post-infection or orally by dissolution of the compoundin the drinking water of the animals, provided adlibitum. Peripheral plasma concentrations were determined by microbiological assay, using Micrococcus luteus seeded in Difco Antibiotic Media 1. Concentrations represent an average value of 5 mice per time period or 6 chicks per time period.
20-Deoxo-20-(diisobutylamino)desmycosin (16) Desmycosin (3.0 g, 3.9 mmol) was dissolved in methanol (30 ml) in the presence of 3A molecular sieves. Diisobutylamine (1.5g, 1 1.7mmol) was added, and after 15 minutes, sodium cyanoborohydride (0.74g, 1 1.7mmol) was added. After being stirred at room temperature for 17 hours, the mixture was filtered, and the filtrate was evaporated to dryness. The resultant yellow solid foam was dissolved in ethyl acetate (200 ml) and extracted with water (200 ml); the product was then extracted into aqueous sodium dihydrogen phosphate buffer solution (250ml, pH 6.5, 0.5 m). The aqueous solution was separated and residual ethyl acetate wasevaporated under reduced pressure. The resultant solution wasrapidly stirred while aqueous sodium hydroxide (5 n) was added to precipitate the desired product; final pH was approximately 8. The white solid was filtered and dried to give 1.34g (39%) of 20-deoxo-20-(diisobutylamino)desmycosin: See Table 1 for MS, UV and NMRdata; pKa (66% DMF) 7.6 and 9.0. 20-Deoxo-20-morpholinyldesmycosin
Desmycosin (1 1.6g, 15mmol) and morpholine (2.6ml, 30mmol) were dissolved in methanol (100ml) and after 30 minutes, sodium cyanoborohydride (1.25 g, 20 mmol) was added. After being stirred overnight at roomtemperature, solvent was evaporated under reduced pressure. The residue was partitioned between water (150ml) and ethyl acetate (150ml), the aqueous layer was separated, and the organic solution was extracted twice with aqueous sodium phosphate solution (0.5 m, initial pH 6.5, 75 ml each). The combined aqueous layers were evaporated under reduced pressure to remove residual organic solvents and then treated with aqueous sodium hydroxide solution while being vigorously stirred until the pH had been raised to 10. The solid clump of precipitate was extracted with ethyl acetate, and the organic solution was dried, filtered, and evaporated to yield 7.7g (61%) of the desired compound; pKa (66% DMF) 6.5 and 8.5.
20-Deoxo-20-neopentylaminodesmycosin (4) The reductive amination was performed as described above, using neopentylamine (3.5 ml, 30 mmol), to yield 8.8g (70%) of the desired product: pKa (66% DMF) 7.9 and 9.7. After the extraction with the pH6.5 phosphate buffer solution, the organic solution was extracted with pH5.5 aqueous phosphate buffer solution which, upon analogous workup, yielded 1.4 g of a mixture of impurities, indicating the potential for selective purification of the desired products by appropriate extractive procedures. To a stirred solution of desmycosin (8.0g, 10.3 mmol) and (bicyclo[2.2.1]hept-2-yl)(rc-octyl)amine (2.5 g, 1 1.1 mmol) in dry methanol (50ml) was added sodium cyanoborohydride (0.7 g, 1 1 mmol) in portions over a five-minute period. The solution was stirred overnight at roomtemperature and solvent was then evaporated under reduced pressure. The residue was dissolved in ethyl acetate (100 ml) and extracted first with water (100ml) and then with 5% aqueous sodium dihydrogen phosphate solution (100ml). The aqueous acidic extract (pH4) was adjusted first to pH6 with 6n sodium hydroxide and extracted with ethyl acetate, then adjusted to pH 7 and extracted with ethyl acetate, and finally adjusted to pH 8 and extracted as before. The organic extract from the pH 7 aqueous solution was dried (magnesiumsulfate) and filtered and the filtrate was evaporated under reduced pressure to yield 4.4 g (45%) of the title compound.
